77 Current news of Sartorius
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
Global political and economic uncertainties substantially increased
22-Apr-2022
Sartorius recorded a dynamic start to fiscal 2022, with sales revenue and earnings posting strong double-digit growth rates in the first quarter compared with the prior-year period. Based on its performance in the first three months, Sartorius confirms its outlook for fiscal 2022. “Sartorius had ...
Sales revenue forecast for 2022 updated due to acquisition
08-Feb-2022
Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasepchromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The ...
Number of employees rises by 30 percent to nearly 14,000
27-Jan-2022
Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability. According to preliminary figures, the company ...
Companies to help bioprocess scientists accelerate clone selection and process development
28-Oct-2021
Waters Corporation and Sartorius announced they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development. Sartorius and Waters will partner to implement the ...
Extension of the Sartorius cell culture media business with a focus on media for gene therapeutics and vaccines
04-Aug-2021
Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist XellAG headquartered in Bielefeld, Germany. XellAG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene ...
Significant double-digit increases in sales and earnings
22-Jul-2021
Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake. “In the first six months of the year, we have seen unabated high demand for innovative technologies used in the development and ...
Group management raises sales target for 2025 to about 5 billion euros
29-Jan-2021
Sartorius recorded high growth according to preliminary figures in 2020 due to strong organic development, several acquisitions and the additional momentum from business related to the coronavirus pandemic. The Group closed the year with significant double-digit growth rates in sales revenue, ...
Positive development of the Lab Products & Services Division
21-Oct-2020
Sartorius closed the first nine months of 2020 with significant double-digit growth rates in sales revenue and earnings. “In the third quarter, we saw high demand for nearly our entire product range,” said Joachim Kreuzburg, CEO. “On top of overall strong organic growth, additional momentum was ...
BIA Separations will be Sartorius’ center of excellence for purification of cell and gene therapeutics
05-Oct-2020
Sartorius announced it has entered into a definitive agreement to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transaction totaling 360 million euros of which 240 million euros will be paid in cash and 120 million euros in Sartorius Stedim Biotech ...
Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group
17-Jul-2020
Based on the strong performance of the Bioprocess Solutions Division in the first half of 2020 as well as on high demand also expected to continue for the rest of the current fiscal year, Sartorius raised its full-year sales and earnings guidance for this division and thus for the entire Group. ...
